| Aug 14 |
Oragenics Inc. Shows Concussion Drug, ONP-002, Designed for Acute Field-Delivery Stable Across a Wide Temperature Range
|
| Aug 12 |
Oragenics, Inc. Announces Concussion Drug Successfully Completes FDA-Required Genotoxicity Study
|
| Aug 9 |
Oragenics: Q2 Earnings Snapshot
|
| Aug 8 |
Oragenics Inc. Announces Concussion Drug, ONP-002, Successfully Clears FDA-Required Cardiotoxicity Testing
|
| Aug 8 |
EXCLUSIVE: Oragenics' Concussion Drug Clears FDA-Required Cardiotoxicity Testing, Planning For Phase II Trials Underway
|
| Jul 10 |
Oragenics Improves Intranasal Drug Formulation for Treating Concussed Patients
|
| Jun 25 |
Why Oragenics (OGEN) Shares Are Falling
|
| Jun 20 |
Oragenics announces NYSE American acceptance of plan of compliance
|
| Jun 20 |
Oragenics, Inc. Announces NYSE American Acceptance of Plan of Compliance
|
| May 22 |
Oragenics Appoints William “Frank” Peacock MD as Chief Clinical Officer
|
